Apheresis is a medical process that involves the purification or separation of different blood components. It entails withdrawing blood from a donor or patient via Venipuncture and collecting it in equipment that separates the desired material from the blood. At the end of the procedure, the remaining blood and other components are returned to the donor or patient. The global apheresis market was worth $1.97 billion in 2021 and is expected to be worth $3.87 billion by 2030, displaying a 7.78% CAGR from 2021 to 2030.
According to The American Society for Apheresis, apheresis can be a supportive treatment for over 87 diseases. Furthermore, according to the United States National Library of Medicine, as of January 21, 2021, there are approximately 47 clinical trials related to apheresis for various hematological diseases across the United States National Library of Medicine.
Key industry drivers
The increasing number of diseases, increased demand for blood components and their associated safety, technological advancements. In the development of new apheresis methods, and increased reimbursement policies and funding for apheresis procedures. Are all driving factors for the growth of the apheresis market. For example, NHS England in the United Kingdom has chosen the automated red blood cell exchange (RBCX) treatment performed on the company’s Spectra Optia Apheresis System to treat sickle cell disease in June 2022 through the NHS MedTech Funding Mandate (MTFM). Patients with sickle cell disease will now have easier access to this treatment. Apheresis-related funding initiatives are thereby fueling the market’s expansion. Along with these elements, rising product innovations and regulatory approvals have been fueling market expansion.
The high cost of apheresis devices, therapeutic apheresis procedures, and apheresis device installation is expect to suppress market growth. In addition, fewer blood donations using apheresis are expect to challenge the apheresis market due to a lack of awareness.
An increase in demand for plasma-derive medicines presents significant prospects for market expansion. The growth in the prevalence of chronic diseases, the rise in surgical procedures, and the rise in accidents and injuries are all driving the market’s expansion.
- Based on product, disposables and reagents generated the most income in 2020, and this trend is likely to continue throughout the forecasted period. Furthermore, the centrifugal apheresis devices category is expect to grow at the fastest CAGR during the anticipate period.
- Blood collection centers and blood component providers accounted for 67.5 percent of the global market in 2020 in terms of End-Users. It is attribute to an increase in the number of blood component testing instruments, an increase in the number of blood centers, and increasing public knowledge of blood collection facilities.
- Plasmapheresis had the greatest market share by application, accounting for approximately 50.0 percent of the total market in 2020. Grifols pioneered plasmapheresis in 1951 to separate plasma from blood cells. The increased prevalence of blood-related disorders, as well as the growing demand for plasma-derived medicines, are the market’s primary growth drivers.
- According to technology, the centrifugation process account for the biggest market share and is expect to remain during the estimate period. This is because centrifugation is widely use in the single-step heavy spin preparation of blood components such as fresh frozen plasma (FFP) and packed red blood cells (PRBCs). Membrane separation is expect to grow quickly over the forecast period because membrane filters are require to separate plasma from other cellular components to accomplish exact cell separation.
North America controls the largest share of the market. The rising prevalence of blood-related ailments such as kidney disease, cancer, and neurological disorders, as well the presence of sophisticated. Healthcare infrastructure and high patient awareness levels, are the key drivers driving market expansion in North America. As per research by the Centers for Disease Control and Prevention (CDC) in 2019. The chronic renal disease affects around 37 million (15%) persons in the United States (CKD). Furthermore, the Europe apheresis equipment market is estimate to grow at a CAGR of roughly 6.39% between 2020 and 2028.
One person in the United States is diagnose with blood cancer every three minutes, according to the Leukemia& Lymphoma Society. Furthermore, according to the ASCO Post, new instances of leukemia, lymphoma, and myeloma accounted for 9.9% of the estimated 1,806,590. New cancer cases in the United States in 2020.
Key market players in the apheresis market are:
- Asahi Kasei Medical
- Kaneka Corporation
- HemaCare Corporation
- B. Braun Melsungen AG